# A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)

Study · id `cardio:ct-nct06455098` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06455098](<https://clinicaltrials.gov/study/NCT06455098>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06455098

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 354 participants.

## Technical summary

Registry record NCT06455098. Allocation not applicable; no masking; primary purpose treatment. Start 2024-06-28 (actual); primary completion 2027-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 354 participants (enrolled count; ClinicalTrials.gov record NCT06455098, source copy `cardio:ctgov-nct06455098-2026-09-25`, retrieved 2026-10-26)
- Started: 2024-06-28 (actual) (ClinicalTrials.gov record NCT06455098, source copy `cardio:ctgov-nct06455098-2026-09-25`, retrieved 2026-10-26)
- Primary completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT06455098, source copy `cardio:ctgov-nct06455098-2026-09-25`, retrieved 2026-10-26)
- Completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT06455098, source copy `cardio:ctgov-nct06455098-2026-09-25`, retrieved 2026-10-26)
- Countries: United States; Australia (ClinicalTrials.gov record NCT06455098, source copy `cardio:ctgov-nct06455098-2026-09-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06455098-2026-09-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
- Acronym: OMNY-AF
- Condition: Atrial Fibrillation
- Intervention (Device): OMNYPULSE™ Catheter with the TRUPULSE Generator
- Lead sponsor: Biosense Webster, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Biosense Webster, Inc. (`cardio:org-biosense-webster-inc`)

## Provenance

Content hash: 1a6749bcf3d2c452b72cb071442bf38d09b3d9c24e71516a26dfeb770c09ac67
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
